Using Client Centricity As Fuel For Innovative Biologics Development And Manufacturing Solutions

By Dr. Marvin Kadisch, Senior Director Process Science Upstream, Dr. Martin Pannek, Director Analytical Science, Dr. Alina Handl, Process Manager Upstream, Dr.-Ing. Marc Hein, Process Manager Upstream, Björn Koselack, Process Manager Downstream, Dr. Aileen Roth, Project Analytics Manager

As biologic therapies grow more complex, development and manufacturing strategies must evolve to keep pace with scientific, regulatory, and commercial demands. This piece explores how a client‑centric operating model — grounded in Quality by Design (QbD), advanced analytics, and flexible process platforms — can accelerate innovation while safeguarding product quality. It examines the technical and organizational challenges associated with both standard antibodies and highly complex, heterogeneous molecules, including the rise of perfusion‑mode manufacturing and continuous bioprocessing.

Through real‑world case examples, readers gain insight into how early identification of critical quality attributes (CQAs), data‑driven process optimization, and close cross‑functional collaboration help maintain comparability during scale‑up and technology transfer. The discussion also highlights how tailored upstream, downstream, and analytical strategies enable manufacturers to manage increasing molecular complexity without compromising timelines or compliance.

Designed for biopharma leaders navigating late‑stage development and clinical manufacturing, this perspective connects scientific rigor with operational adaptability.

Discover how embedding client needs into development strategies can support scalability, reduce risk, and ultimately help bring advanced biologics to patients more efficiently.